Divi's Laboratories Q2 Results: Profit Jumps 47%, Beats Estimates

Divi's Laboratories Ltd. reported a 47% surge in its net profit to beat the street's expectations for the second quarter of the financial year 2025 driven by a consistent rise in sales by the pharmaceutical major.

Shares of Divi's Labs closed 0.17% lower at Rs 5,949.8 on Friday on the National Stock Exchange compared to a 0.21% decline in the benchmark NSE Nifty 50 index.

The stock has risen 70% during the last 12 months and has advanced by 52% on a year-to-date basis. The relative strength index was at 60.

Eight out of the 27 analysts tracking the company has a 'buy' rating on the stock, six suggest a 'hold' and 13 have a 'sell', according to Bloomberg data. The average of 12-month analyst price targets implies a potential downside of 22%.